Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge?
Immune checkpoint inhibitor
Myocarditis
Myositis
Troponin
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
21
02
2023
received:
12
01
2023
accepted:
05
03
2023
medline:
31
7
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
A 54-year old patient with metastatic melanoma presented with asymptomatic myositis and myocarditis after combined immune checkpoint inhibitors (ICI) therapy (anti-programmed cell death receptor-1, anti-lymphocyte activating gene-3, and anti-indoleamine 2,3-dioxygenase-1). The diagnosis was based on the typical time window after ICI, recurrence upon re-challenge, elevations of CK, high-sensitive troponin T (hs-TnT) and I (hs-TnI), mild NT-proBNP increase, and positive magnetic resonance imaging criteria. Notably, hsTnI was found to more rapidly increase and fall and to be more heart-specific than TnT in the context of ICI-related myocarditis. This led to ICI therapy withdrawal and switch to a less effective systemic therapy. This case report highlights the differential value of hs-TnT and hs-TnI for diagnosis and monitoring of ICI-related myositis and myocarditis.
Identifiants
pubmed: 37021424
doi: 10.1002/ehf2.14360
pmc: PMC10375180
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Troponin T
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2680-2685Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Eur J Heart Fail. 2020 Nov;22(11):1966-1983
pubmed: 33006257
Eur J Cancer. 2020 Jan;124:15-24
pubmed: 31707280
Circ Cardiovasc Imaging. 2018 Jul;11(7):e007598
pubmed: 30012826
Lancet Oncol. 2018 Sep;19(9):e447-e458
pubmed: 30191849
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
BMC Cancer. 2019 Jun 10;19(1):558
pubmed: 31182061
Am Heart J. 2013 Sep;166(3):541-8
pubmed: 24016505
J Am Coll Cardiol. 2017 Aug 1;70(5):558-568
pubmed: 28750699
ESC Heart Fail. 2023 Aug;10(4):2680-2685
pubmed: 37021424
Am J Cardiol. 2016 Sep 15;118(6):816-821
pubmed: 27453509
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Inflamm Bowel Dis. 2018 Jul 12;24(8):1695-1705
pubmed: 29718308
Eur J Heart Fail. 2021 Oct;23(10):1725-1735
pubmed: 34114291
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
JACC CardioOncol. 2022 Dec 20;4(5):689-700
pubmed: 36636441
J Appl Lab Med. 2020 Jan 1;5(1):239-241
pubmed: 32445337
Lancet Oncol. 2017 Apr;18(4):435-445
pubmed: 28284557
JACC CardioOncol. 2022 Dec 20;4(5):673-685
pubmed: 36636435
Cardiovasc Res. 2019 Apr 15;115(5):854-868
pubmed: 30715219
Eur Heart J. 2022 Nov 1;43(41):4229-4361
pubmed: 36017568
Circulation. 2022 Oct 11;146(15):e204
pubmed: 36214135